VX-961 / Vertex - LARVOL DELTA

"Did $VRTX discontinue VX-150 (after discontinuing VX-961)? So VX-548 is its third shot at Nav1.8?" (@JacobPlieth)

Vertex drops VX-961 to continue search for perfect pain drug (FierceBiotech) - "Vertex has stopped development of VX-961 after getting a look at phase 1 data....Vertex will open a new stage of its search for the perfect NaV1.8 inhibitor when it moves another of VX-150’s siblings into phase 1 later in the first half of 2020. Data from that trial will inform Vertex’s decision about which pain drug to advance into later-stage development."

Discontinued • New P1 trial

Product discontinued (Businesswire) - Pain

Vertex reports third-quarter 2019 financial results (Businesswire) - "A Phase 1 study is ongoing in healthy volunteers evaluating the investigational NaV1.8 inhibitor VX-961 for the treatment of pain. VX-961 has been granted Fast Track Designation by the FDA."

Fast track designation • Trial status